Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Grows By 35.8%

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 250,300 shares, an increase of 35.8% from the February 13th total of 184,300 shares. Approximately 11.2% of the shares of the company are sold short. Based on an average daily volume of 850,600 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analyst Weigh In

GTBP has been the topic of a number of research analyst reports. Roth Mkm initiated coverage on shares of GT Biopharma in a report on Monday, December 2nd. They issued a “buy” rating and a $11.00 target price on the stock. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a report on Monday, December 2nd.

GT Biopharma Stock Performance

GTBP traded down $0.04 on Tuesday, reaching $2.37. The company had a trading volume of 21,176 shares, compared to its average volume of 578,983. GT Biopharma has a fifty-two week low of $1.72 and a fifty-two week high of $10.66. The stock has a market cap of $6.00 million, a P/E ratio of -0.34 and a beta of 0.59. The company’s fifty day moving average is $2.31 and its 200 day moving average is $2.49.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.